

**ondine**



**For Immediate Release**

**Ondine Announces Publication of Positive Results from  
*Pseudomonas aeruginosa* Eradication Study**

**Vancouver, Canada – August 7, 2008** - Ondine Biopharma Corporation (TSX: OBP; AIM: OBP) today announced that the results of a study using the Company's platform Photodisinfection technology to eliminate *Pseudomonas aeruginosa* will be published in the peer-reviewed journal Photochemistry and Photobiology. The article has been e-published ahead of the print version and is currently available online at <http://www3.interscience.wiley.com/journal/120121002/issue>.

*P. aeruginosa* is an opportunistic pathogen renowned for being able to live in practically any environment, including distilled water or even some hospital disinfectant solutions. It is notorious for being resistant to almost all antibiotics, and it is often the source of intractable infections in cystic fibrosis patients where the fatality rate can approach 50%. In the recently published article entitled "*In Vitro* Photodynamic Eradication of *Pseudomonas aeruginosa* in Planktonic and Biofilm Culture", Ondine researchers conclusively demonstrated rapid eradication of *P. aeruginosa* in both free-floating (planktonic) and the highly-resistant biofilm forms.

"We believe that Ondine's platform photodisinfection technology can scale to address numerous clinically-unmet needs," stated Dr. Cale Street, Ondine's Director of Research. "Pseudomonads can cause dangerous infections in humans including respiratory infections, burn and wound infections, bacteremias, severe external ear infections, and bone and joint infections. Pseudomonads are one of the most difficult to kill microorganisms. Our photodisinfection technology has proven capable of eradicating this virulent pathogen in short time periods, without producing dangerous by-products. In addition, Photodisinfection does not induce the bacterial resistance factors that compromise antibiotics today. Our recent publication highlights the rigorous approach we take to research and development, and adds to the peer-reviewed literature available to our potential strategic partners for additional photodisinfection indications."

**About Ondine Biopharma Corporation**

Ondine is developing non-antibiotic therapies for the treatment of a broad spectrum of bacterial, fungal and viral infections. The Company is focused on developing and commercializing leading edge products utilizing its patented light-activated technology. Photodisinfection provides broad-spectrum antimicrobial efficacy without encouraging the formation and spread of antibiotic resistance. The Company is based in Vancouver, British Columbia, Canada, with a research laboratory in Bothell, Washington, and an international office in St Michael, Barbados. For additional information, please visit the Company's website at: [www.ondinebiopharma.com](http://www.ondinebiopharma.com)

**Forward-Looking Statements:**

*Certain statements contained in this release containing words like "believe", "intend", "may", "expect" and other similar expressions, are forward-looking statements that involve a number of risks and uncertainties. Factors that could cause actual results to differ materially from those projected in the Company's forward-looking statements include the following: market acceptance of our technologies and products; our ability to obtain financing; our financial and technical resources relative to those of our competitors; our ability to keep up with rapid technological change; government regulation of our technologies; our ability to enforce our intellectual property rights and protect our proprietary technologies; the ability to obtain and develop partnership opportunities; the timing of commercial product launches; the ability to achieve key technical milestones in key products and other risk factors identified from time to time in the Company's filings.*

The TSX Exchange has not reviewed and does not accept responsibility for the adequacy or accuracy of this release.

**FOR FURTHER INFORMATION please contact:**

Carolyn Cross  
President and  
Chief Executive Officer  
Ondine Biopharma Corporation  
(604) 669-0555  
ccross@ondinebiopharma.com

Adam Peeler  
Investor Relations  
The Equicom Group Inc.  
(416) 815-0700 ext. 225  
apeeler@equicomgroup.com

Canaccord Adams Ltd  
Nominated Adviser &  
Broker  
Neil Johnson /  
Ryan Gaffney  
+4420 7050 6500